Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.86 USD | +3.49% | -1.28% | +9.97% |
Financials (USD)
Sales 2024 * | 24.88M | Sales 2025 * | 32.7M | Capitalization | 229M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | -25M | EV / Sales 2024 * | 9.22 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.01 x |
P/E ratio 2024 * |
-21.4
x | P/E ratio 2025 * |
-9.32
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.9% |
Latest transcript on Aldeyra Therapeutics, Inc.
1 day | +3.49% | ||
1 week | -1.28% | ||
1 month | -8.10% | ||
3 months | -8.53% | ||
6 months | +34.97% | ||
Current year | +9.97% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Brady
CEO | Chief Executive Officer | 52 | 05-08-31 |
Bruce Greenberg
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Caitlin Pazzano
PRN | Corporate Officer/Principal | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 58 | 09-04-30 |
Martin Joyce
BRD | Director/Board Member | 70 | 13-09-30 |
Ben Bronstein
BRD | Director/Board Member | 74 | 10-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.86 | +3.49% | 274,081 |
24-05-30 | 3.73 | +0.81% | 165,944 |
24-05-29 | 3.7 | -2.37% | 256,031 |
24-05-28 | 3.79 | -3.07% | 310,511 |
24-05-24 | 3.91 | +3.17% | 260,694 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.97% | 229M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ALDX Stock